Clinical Updatesbevacizumaberlotinib
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer: New Therapeutic Prospects
By MedXY|Sep 30, 2025
A phase 2 study shows that bevacizumab and erlotinib combination therapy offers notable tumor responses and survival benefits in both hereditary and sporadic papillary renal-cell carcinoma, with manageable toxicity.